Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interferenc...
| Main Authors: | , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2016
|
| Online Access: | http://hdl.handle.net/1721.1/105539 https://orcid.org/0000-0002-0013-3941 https://orcid.org/0000-0002-1090-6071 |
| _version_ | 1826207722890067968 |
|---|---|
| author | Sockolosky, Jonathan T. Ho, Chia Chi M. Almo, Steven C. Garcia, K. Christopher Dougan, Michael Kauke, Monique Jacqueline Ploegh, Hidde Ingram, Jessica R. |
| author2 | Massachusetts Institute of Technology. Department of Biology |
| author_facet | Massachusetts Institute of Technology. Department of Biology Sockolosky, Jonathan T. Ho, Chia Chi M. Almo, Steven C. Garcia, K. Christopher Dougan, Michael Kauke, Monique Jacqueline Ploegh, Hidde Ingram, Jessica R. |
| author_sort | Sockolosky, Jonathan T. |
| collection | MIT |
| description | Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interference with the CD47–SIRPα interaction synergizes with tumor-specific monoclonal antibodies to eliminate human tumor xenografts by enhancing macrophage-mediated antibody-dependent cellular phagocytosis (ADCP), but synergy between CD47 blockade and ADCP has yet to be demonstrated in immunocompetent hosts. Here, we show that CD47 blockade alone or in combination with a tumor-specific antibody fails to generate antitumor immunity against syngeneic B16F10 tumors in mice. Durable tumor immunity required programmed death-ligand 1 (PD-L1) blockade in combination with an antitumor antibody, with incorporation of CD47 antagonism substantially improving response rates. Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy. |
| first_indexed | 2024-09-23T13:53:57Z |
| format | Article |
| id | mit-1721.1/105539 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T13:53:57Z |
| publishDate | 2016 |
| publisher | National Academy of Sciences (U.S.) |
| record_format | dspace |
| spelling | mit-1721.1/1055392022-09-28T16:56:06Z Durable antitumor responses to CD47 blockade require adaptive immune stimulation Sockolosky, Jonathan T. Ho, Chia Chi M. Almo, Steven C. Garcia, K. Christopher Dougan, Michael Kauke, Monique Jacqueline Ploegh, Hidde Ingram, Jessica R. Massachusetts Institute of Technology. Department of Biology Massachusetts Institute of Technology. Department of Chemical Engineering Whitehead Institute for Biomedical Research Koch Institute for Integrative Cancer Research at MIT Dougan, Michael Kauke, Monique Jacqueline Ploegh, Hidde Ingram, Jessica R. Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interference with the CD47–SIRPα interaction synergizes with tumor-specific monoclonal antibodies to eliminate human tumor xenografts by enhancing macrophage-mediated antibody-dependent cellular phagocytosis (ADCP), but synergy between CD47 blockade and ADCP has yet to be demonstrated in immunocompetent hosts. Here, we show that CD47 blockade alone or in combination with a tumor-specific antibody fails to generate antitumor immunity against syngeneic B16F10 tumors in mice. Durable tumor immunity required programmed death-ligand 1 (PD-L1) blockade in combination with an antitumor antibody, with incorporation of CD47 antagonism substantially improving response rates. Our results highlight an underappreciated contribution of the adaptive immune system to anti-CD47 adjuvant therapy and suggest that targeting both innate and adaptive immune checkpoints can potentiate the vaccinal effect of antitumor antibody therapy. National Institutes of Health (U.S.) (Grant R01 CA177684) Virginia and D.K. Ludwig Fund for Cancer Research Lustgarten Foundation National Institutes of Health (U.S.) (Massachusetts General Hospital Division of Gastroenterology. Training Grant T32 DK007191) 2016-12-02T20:15:13Z 2016-12-02T20:15:13Z 2016-04 2016-02 Article http://purl.org/eprint/type/JournalArticle 0027-8424 1091-6490 http://hdl.handle.net/1721.1/105539 Sockolosky, Jonathan T. et al. “Durable Antitumor Responses to CD47 Blockade Require Adaptive Immune Stimulation.” Proceedings of the National Academy of Sciences 113.19 (2016): E2646–E2654. © 2016 National Academy of Sciences https://orcid.org/0000-0002-0013-3941 https://orcid.org/0000-0002-1090-6071 en_US http://dx.doi.org/10.1073/pnas.1604268113 Proceedings of the National Academy of Sciences Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf National Academy of Sciences (U.S.) PNAS |
| spellingShingle | Sockolosky, Jonathan T. Ho, Chia Chi M. Almo, Steven C. Garcia, K. Christopher Dougan, Michael Kauke, Monique Jacqueline Ploegh, Hidde Ingram, Jessica R. Durable antitumor responses to CD47 blockade require adaptive immune stimulation |
| title | Durable antitumor responses to CD47 blockade require adaptive immune stimulation |
| title_full | Durable antitumor responses to CD47 blockade require adaptive immune stimulation |
| title_fullStr | Durable antitumor responses to CD47 blockade require adaptive immune stimulation |
| title_full_unstemmed | Durable antitumor responses to CD47 blockade require adaptive immune stimulation |
| title_short | Durable antitumor responses to CD47 blockade require adaptive immune stimulation |
| title_sort | durable antitumor responses to cd47 blockade require adaptive immune stimulation |
| url | http://hdl.handle.net/1721.1/105539 https://orcid.org/0000-0002-0013-3941 https://orcid.org/0000-0002-1090-6071 |
| work_keys_str_mv | AT sockoloskyjonathant durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation AT hochiachim durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation AT almostevenc durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation AT garciakchristopher durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation AT douganmichael durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation AT kaukemoniquejacqueline durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation AT ploeghhidde durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation AT ingramjessicar durableantitumorresponsestocd47blockaderequireadaptiveimmunestimulation |